Delayed
Toronto S.E.
11:00:00 2024-04-16 am EDT
|
5-day change
|
1st Jan Change
|
0.055
CAD
|
-.--%
|
|
-21.43%
|
-15.38%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9.651
|
8.744
|
7.257
|
8.826
|
2.977
|
3.875
|
Enterprise Value (EV)
1 |
7.232
|
9.141
|
7.8
|
9.233
|
3.277
|
4.671
|
P/E ratio
|
-2.95
x
|
-2.67
x
|
-3.69
x
|
-1.83
x
|
-3.54
x
|
-11.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
79.7
x
|
34.6
x
|
20.5
x
|
25
x
|
8.42
x
|
11
x
|
EV / Revenue
|
59.7
x
|
36.2
x
|
22
x
|
26.1
x
|
9.26
x
|
13.2
x
|
EV / EBITDA
|
-2.64
x
|
-3.03
x
|
-5.78
x
|
-4.01
x
|
-2.35
x
|
-3.37
x
|
EV / FCF
|
-5.71
x
|
-4.59
x
|
-29.7
x
|
-5.48
x
|
-5.64
x
|
-3.89
x
|
FCF Yield
|
-17.5%
|
-21.8%
|
-3.37%
|
-18.3%
|
-17.7%
|
-25.7%
|
Price to Book
|
-21.2
x
|
-2.75
x
|
-1.28
x
|
-1.17
x
|
-0.56
x
|
-1.28
x
|
Nbr of stocks (in thousands)
|
26,800
|
30,646
|
33,523
|
38,531
|
42,750
|
65,002
|
Reference price
2 |
0.3601
|
0.2853
|
0.2165
|
0.2291
|
0.0696
|
0.0596
|
Announcement Date
|
4/30/19
|
7/31/20
|
4/30/21
|
6/28/22
|
5/1/23
|
5/17/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.1211
|
0.2526
|
0.3537
|
0.3537
|
0.3537
|
0.3537
|
EBITDA
1 |
-2.736
|
-3.016
|
-1.349
|
-2.3
|
-1.395
|
-1.385
|
EBIT
1 |
-2.739
|
-3.018
|
-1.35
|
-2.301
|
-1.396
|
-1.386
|
Operating Margin
|
-2,261.75%
|
-1,194.67%
|
-381.75%
|
-650.57%
|
-394.51%
|
-391.89%
|
Earnings before Tax (EBT)
1 |
-2.769
|
-2.954
|
-1.58
|
-4.073
|
-0.7432
|
-0.3117
|
Net income
1 |
-2.769
|
-2.954
|
-1.58
|
-4.073
|
-0.7432
|
-0.3117
|
Net margin
|
-2,286.34%
|
-1,169.3%
|
-446.74%
|
-1,151.52%
|
-210.11%
|
-88.13%
|
EPS
2 |
-0.1222
|
-0.1067
|
-0.0586
|
-0.1254
|
-0.0197
|
-0.005262
|
Free Cash Flow
1 |
-1.266
|
-1.994
|
-0.2627
|
-1.686
|
-0.5806
|
-1.201
|
FCF margin
|
-1,045.47%
|
-789.18%
|
-74.26%
|
-476.61%
|
-164.14%
|
-339.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
7/31/20
|
4/30/21
|
6/28/22
|
5/1/23
|
5/17/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.4
|
0.54
|
0.41
|
0.3
|
0.8
|
Net Cash position
1 |
2.42
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.1315
x
|
-0.402
x
|
-0.177
x
|
-0.2151
x
|
-0.5754
x
|
Free Cash Flow
1 |
-1.27
|
-1.99
|
-0.26
|
-1.69
|
-0.58
|
-1.2
|
ROE (net income / shareholders' equity)
|
714%
|
175%
|
33.3%
|
68.4%
|
11.7%
|
5.97%
|
ROA (Net income/ Total Assets)
|
-84.1%
|
-103%
|
-182%
|
-284%
|
-125%
|
-160%
|
Assets
1 |
3.294
|
2.855
|
0.8673
|
1.434
|
0.5922
|
0.1954
|
Book Value Per Share
2 |
-0.0200
|
-0.1000
|
-0.1700
|
-0.2000
|
-0.1200
|
-0.0500
|
Cash Flow per Share
2 |
0.0900
|
0
|
0
|
0.0100
|
0.0100
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
7/31/20
|
4/30/21
|
6/28/22
|
5/1/23
|
5/17/24
|
|
1st Jan change
|
Capi.
|
---|
| +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|